Genomic Health Licenses Almac's Technology to Develop New Test | GenomeWeb

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Monday that it is exclusively licensing Almac Group's technology and intellectual property to develop a multi-gene test for the prediction of benefits from DNA damage-based chemotherapy drugs.

Genomic Health will also validate and validate the test, which is focused on drugs such as the commonly used anthracycline-based regimens. The company said such a test would be especially useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.